Chart-Typ:
Zeitraum:
| Oruka Therapeutics, Inc.: Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing | PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4 Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001... ► Artikel lesen |
| Oruka Therapeutics, Inc.: Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer | MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard... ► Artikel lesen |
| Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen |
| Palvella Therapeutics Inc.: Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer | Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas Leader in pediatric dermatology with nearly 20 years of distinguished... ► Artikel lesen |
| Palvella Therapeutics Inc.: Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations | QTORIN rapamycin has the potential to become the first FDA-approved therapy and establish a new standard of care for an estimated more than 30,000 pediatric and adult patients living with microcystic... ► Artikel lesen |
| Palvella Therapeutics Inc.: Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | First module of the rolling NDA for QTORIN rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA submission on track for the second half of 2026 Preparing... ► Artikel lesen |
| Neurogene Inc.: Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress | New presentations to highlight rapid transgene expression of full-length MECP2 following single-stranded AAV delivery and evaluation of miRNA-based approaches to regulating MeCP2 expression on a... ► Artikel lesen |
| Der frühe Vogel fängt den Wurm: 10-mal "Kaufen" und bis zu 540 Prozent Potenzial - jetzt zugreifen? | © Foto: DALL-ENach einem Kursrutsch von rund 32 Prozent wittern Analysten eine massive Chance. Zehn Experten sagen "Kaufen", das durchschnittliche Kursziel verspricht fast 200 Prozent Potenzial. Enthaltene... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PARDES BIOSCIENCES INC finden Sie auf Wallstreet Online.